drugset / Trial / NCT07345442

Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects

NCT07345442

Phase 1 Completed 36 enrolled Anhui Palo Alto Pharmaceuticals, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult

Timeline

Start
2025-03-14
Primary completion
2025-06-09
Completion
2025-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PA9159 Small molecule 80 ug Intranasal
Subject PA9159 Small molecule 160 ug Intranasal
Subject PA9159 Small molecule 320 ug Intranasal

Indications